Observational studyDeutsches Arzteblatt international2024
Cannabis Use in Germany.
Observational study in Deutsches Arzteblatt international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Stigma toward individuals with cannabis use disorder across age groups: associations with familiarity and sociodemographic characteristics.Harm reduction journal · 2026Article
- Who is at risk? Core mental health symptoms and problematic cannabis use in Germany.Journal of cannabis research · 2026Article
- Prevalence and factors associated with tobacco and cannabis co-use in France: Results from a national representative survey.Drug and alcohol dependence reports · 2025Article
- Cannabis Consumption Before and After Partial Legalization in Germany: Early Trends, Consumption Patterns, and Motives.Deutsches Arzteblatt international · 2025Article
- What proportion of people who use cannabis in Germany have spoken with their general practitioner about their consumption? A repeated cross-sectional representative population survey.Journal of cannabis research · 2025Article
- High acceptance and reported efficacy of cannabis for pain management in patients with rheumatic diseases in Germany: a postlegalisation survey.EULAR rheumatology open · 2025Article
- Cannabis use among adolescents and young adults in Germany: Study results and prevention measures offered by the Federal Institute of Public Health.Journal of health monitoring · 2025Article
- Association of cigarette and e-cigarette use with cannabis-related risk perceptions and intentions.Journal of cannabis research · 2025Article
- Unseen dualities: underdiagnosis of substance use disorders in borderline personality disorder.Frontiers in psychiatry · 2025Article
- In Reply.Deutsches Arzteblatt international · 2024Article
- Cannabis Consumption Rates were Underestimated.Deutsches Arzteblatt international · 2024Article
- Germany's cannabis act: a catalyst for European drug policy reform?The Lancet regional health. Europe · 2024Review
- Problematic Consumption of Alcohol, Cannabis and Cigarettes—a German Nationwide Survey on Psychopathology, Stress, Mindfulness, and Quality of Life.Deutsches Arzteblatt international · 2024Article
- Road safety implications of the partial legalisation of cannabis in Germany: protocol for a quasi-experimental study.BMJ open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe federal government of Germany is planning to liberalize the recreational cannabis market for adults. We aimed to collect key baseline data on frequency of use, routes of administration, and co-use of cannabis and inhaled nicotine or tobacco products in the population.
methodsBased on data from a national survey of 9644 people aged >14 years, we analyzed self-reported use of cannabis in the past 12 months and preferred route of administration (single choice: smoked with tobacco; smoked without tobacco; inhaled without tobacco; consumed with food; consumed in another form).
resultsThe prevalence of past-year cannabis use was 4.6% (95% CI [4,2; 5,1%]), with higher rates among 14-24- (11.4%) and 25-39-year-olds (8.2%) as well as among co-users of inhaled nicotine or tobacco products, particularly waterpipe users (27.0%). Smoking cannabis with or without tobacco was the preferred route of administration, reported by 92.4% (95% CI [89,6; 94,6%]). It was most frequently reported by 14-24-year-olds and by co-users of inhaled nicotine or tobacco products.
conclusionSmoking remains the predominant form of using cannabis-especially among younger users, who are at greatest risk of cannabis-related consequences. The true prevalence of cannabis use may have been underestimated in our study, however, as not all participants answered the questions on cannabis. Nevertheless, preventive and harm reduction efforts are needed to reduce the harm from using cannabis. Continuous monitoring is required to evaluate the effects of the forthcoming law changes in Germany.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.